Drug discovery and development company, Blueberry Therapeutics, has secured a GBP3.6 million extension to its previously successful GBP10.8 million Series B fundraising.
Japanese investor, Medical Incubator Japan (MIJ), and a private syndicate of US Board Certified Dermatologists – led by Dr Omar Ibrahimi of the Connecticut Skin Institute – have invested GBP3.1 million and GBP500k, respectively.
BB2603 is Blueberry Therapeutics lead drug candidate and is now in Phase II of clinical development. It is designed to enhance the delivery of terbinafine – an anti-fungal medicine – under the nail and to treat infections quickly and effectively, using a smaller dose.
The additional GBP3.6m funding will support the Phase II dose-finding study, ahead of Phase III clinical development in the US and EU for the treatment of onychomycosis.
Read more at: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.